Search Results

Factor Bioscience Inc. today announced that the United States Patent and Trademark Office (USPTO) has terminated three separate ex parte reexaminations of three U.S. patents owned by Factor.

Factor Bioscience Inc. today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting to be held in Baltimore, MD from May 7-11, 2024.

Factor Bioscience Inc. announced the award of a U.S. Department of Defense grant to develop next-generation cell therapy candidates using Factor’s patented mRNA, cell-reprogramming, and gene-editing technologies.

On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment...

UCB, a global biopharmaceutical company, will present results from three studies for CIMZIA®, a PEGylated fragment crystalized -free tumor necrosis factor inhibitor, for women of childbearing age living with chronic immune-mediated diseases and people with rheumatoid arthritis and high rheumatoid factor levels.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing.